Concerns Over Sovereignty and Jobs
The proposed sale of 's controlling stake in its consumer health unit, Opella, to . investment fund has ignited fears of losing sovereignty over key medications and potential job losses in .
Critics, including politicians and unions, argue that the government's measures to protect jobs and production in France are insufficient, recalling drug shortages during the .
Government and Public Response
Economy Minister announced a trilateral agreement ensuring Opella's production, research, and workforce remain in France, with financial penalties for non-compliance.
Despite these assurances, public and political skepticism remains, with some lawmakers vowing close parliamentary surveillance and potential measures to block the sale if conditions aren't met.